1 / 42

Quinolones

Quinolones. Prof. Anuradha Nischal. Synthetic antimicrobials Bactericidal Primarily gram negative bacteria. Nalidixic acid. First member. Spectrum. Gram negative bacteria especially coliforms E.coli Proteus Kleibseilla Enterobacter Shigella X psuedomonas. Bactericidal antibiotic.

wilsonpaul
Télécharger la présentation

Quinolones

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Quinolones Prof. Anuradha Nischal

  2. Syntheticantimicrobials • Bactericidal • Primarily gram negative bacteria

  3. Nalidixic acid • First member

  4. Spectrum • Gram negative bacteria especially coliforms • E.coli • Proteus • Kleibseilla • Enterobacter • Shigella • X psuedomonas Bactericidal antibiotic

  5. Concentration of free drug in plasma & most tissues is non-therapeutic for systemicinfections • Therapeutic concentrations attained in urine & gut lumen are lethal to common urinary pathogens & diarrhoea causing coliforms

  6. Therapeutic uses • Urinary antiseptic • Diarrhoea caused by coliforms Norfloxacin/ciprofloxacin preffered Urinary tract infections for many years

  7. Low potency • Narrow spectrum • and rapid developmemt of bacterial resistance. • Limited therapeutic utility • No longer used.

  8. Fluoroquinolones • Fluorination of quinolone structure at position 6 & piperazine substitution at position 7 resulted in derivatives called fluoroquinolones • Important therapeutic advance

  9. High potency • Expanded spectrum/Broad antimicrobial activity • Slow development of resistance • Better tissue penetration & • Good tolerability • Used for wide variety of infectious diseases

  10. Classification First generation Second generation Levofloxacin Lomefloxacin Moxifloxacin Sparfloxacin Gemifloxacin Prulifloxacin Norfloxacin Ciprofloxacin Ofloxacin Pefloxacin

  11. Mechanism of action Quinolones target bacterial DNA gyrase & TopoisomeraseIV • Gram negative bacteria - DNAGyrase • Gram positive bacteria - TopoisomeraseIV

  12. Mammaliancells Topoisomerase II Low affinity for flouroquinolones Inhibited by quinolones only at muchhigher concentrations. Low toxicity to host cells

  13. Mechanism of action • Double helical DNA • Two strands must separate to permit DNA replication / transcription • “over winding” / excessive positive supercoiling of DNA in front of point of seperation (mechanical hindrance) • faulty protein synthesis • Detrimental for bacterial growth.

  14. DNA Gyrase has (A & B subunit) • A subunit - strand cutting function of DNA gyrase. • B subunit - introduces negative supercoils DNA Gyrase - introduces negative supercoils into DNA (checks mechanical hindrance) • A subunit reseals the strand

  15. Quinolones • bind to A - subunit with high affinity & interfere with strand cutting & resealing function • Prevent replication of bacterial DNA during bacterial growth & reproduction.

  16. In addition bacterial DNA gyrase inhibition also leads to extensive filamentation vacuole formation & degradation of chromosomal DNA All this confers bactericidal activity to FQ’s

  17. Mechanism ofresistance • Chromosomalmutation bacteria produce DNA Gyrase/ Topoisomerase IV with reduced affinity for FQs • Effluxof these drugs across bacterial membranes • No quinolone modifying/inactivating enzymes have been identified in bacteria • Resistance is slow to develop

  18. Spectrum Potent bactericidal against Gram negative bacteria: • E.coli • Salmonella • Shigella • Enterobacter • Campylobacter & Neisseria Ciprofloxacin is more active against • Pseudomonas aeruginosa

  19. Flouroquinolones also have good activity against • Staph. aureus but not against methicillin resistant strains • Intracellular bacteria are also inhibited • Chlamydia • Mycoplasma • Mycobacterium including Mycobacterium tuberculosis

  20. Levofloxacin • Gatifloxacin • Moxifloxacin Excellent Activity against streptococci Several - anaerobic bacteria • Gemifloxacin • Ofloxacin, Gatifloxacin & Moxifloxacin

  21. Pk • Rapid oral absorption • High tissue penetrability Concentration in lung, sputum, muscle, bone, prostrate, and phagocytes exceeds that in plasma • CSF & aqueous levels are low • Excreted in urine • Urinary & biliary concentrations are 10-50 fold higher than in plasma

  22. Pk • Excreted in urine • Dose adjustment in renal failure • Exception Pefloxacin & moxifloxacin • Metabolized by liver • Should not be used in hepatic failure

  23. Dosage • 200-400 mg every 12 Hrs for Ofloxacin • 400 mg every 12 Hrs for Norfloxacin & Pefloxacin • 250-750 mg every 12 Hrs for Ciprofloxacin • 500 mg OD : Levofloxacin • 400 mg OD : Lomefloxacin • 200-400mg OD : Sparfloxacin • 320 mg OD: Gemifloxacin

  24. Adverse effects • Generally safe • Nausea, vomiting, abdominal discomfort, bad taste • CNS: • headache, dizziness, rarely hallucinations, delirium. • & seizures have occurred predominantly in patients receiving theophylline or a NSAIDs

  25. Adverse effects • Hypersenstivity; rashes including photosenstivity • Tendonitis & tendon rupture • Arthropathy in immature animals, • Use in children contraindicated

  26. Adverse effects • QTc prolongation • Sparfloxacin • Gatifloxacin • Moxifloxacin • Cautious use in patients who are taking drugs that are known to prolong the QT interval tricyclic antidepressants phenothiazines and class I anti-arrhythmics

  27. withdrawn • GatifloxacinHypoglycaemia • Temafloxacin Immune hemolytic anaemia • Trovafloxacin Hepatotoxicity • Grepafloxacin Cardiotoxicity • Clinafloxacin Phototoxicity

  28. Drug interactions • NSAIDs may enhance CNS toxicity of FQ’s • Seizures reported • Antacids, Sucralfate, Iron salts reduce absorption of FQ,s

  29. THERAPEUTIC USES Urinarytractinfections • Most commonly used antimicrobials for UTI • Very effective against Gram negative bacilli like E.coli Proteus Enterobacter Psuedomonas • Norflox 400 mg bd Ciprofloxacin 500 mg bd Ofloxacin 400 mg bd

  30. Prostatitis • Norfloxacin • Ciprofloxacin • Ofloxacin All are effective. FQ’s administered for 4-6 wks.

  31. Quinolones with activity against G +ve bacteria & anaerobes such as • Ofloxacin • Moxifloxacin can be used in infections of the oral cavity

  32. Sexually transmitted diseases Active against • N. gonorrhoea • Chlamydia trachomatis • H. ducreyi • FQ’s lack activity against T. pallidum

  33. GASTROINTESTINAL AND ABDOMINAL INFECTIONS • Traveller’s Diarrhoea • Shigellosis • Diarrhoea in cholera • Peritonitis

  34. Salmonella typhi infection • Ciprofloxacin 500 mg bd x 10 days • Prevents carrier state also • 750 mg bd x 4-8 wks • IN MDR enteric fever-Ceftriaxone,Cefotaxime,Cefixime(oral) and oral Azithromycin can be used. Ofloxacin: 400 mg BD Levofloxacin: 500 mg OD/BD Pefloxacin: 400 mg BD Equally efficacious

  35. Ceftriaxone • Most reliable • Fastest acting bactericidal drug for enteric fever • i.v 4g daily 2 days • 2g daily till 2 days after fever subsides • Preferred drug

  36. Bone, joint, soft tissue & wound infections • Skin & soft tissue infections • Osteomyelitis & joint infections

  37. Respiratory infections • Pneumonia • Acute sinusitis • Chr. Bronchitis • Multi drug resistant TB. • Myco. Avium complex in AIDS pts. • & Leprosy

  38. To conclude • Rapid bactericidal activity • High potency • Long post-antibiotic effect • Low frequency of resistance • Frequently prescribed • Effectively decrease infectious load in the community.

  39. THANK YOU

  40. Norfloxacin • Primarily used for urinary & genital tract infections. • Bacterial diarrhoeas: high concentration in gut & anaerobic flora of gut is not disturbed

  41. Pefloxacin • Methyl derivative of norfloxacin • More lipid soluble • High concentrations in CSF • Preferred for meningeal infections

  42. Postantibiotic effect • The antibacterial effect continues for approximately two to three hours after bacteria are exposed to these drugs, despite subinhibitory concentrations. • The duration of the postantibiotic effect may be increased with longer bacterial drug exposure and higher drug concentrations.

More Related